

## CURRICULUM VITAE

---

### Personalia

Name: Janine Simons  
Date of birth: 08/18/1989  
Place of birth: Naarden, the Netherlands  
Address: Overtoom 2  
2811 LH Reeuwijk, the Netherlands  
Phone number: +31(0)640217315  
Email address: jmsimons@hotmail.com



---

### Education & postgraduate training

Sep 2020 – Feb 2025 Resident in training, Radiation-Oncology, Erasmus Medical Center, Rotterdam, the Netherlands (0.9fte)  
2011 – 2014 Master of Medicine, VU University, Amsterdam, the Netherlands  
2007 – 2010 Bachelor of Medicine, VU University, Amsterdam, the Netherlands  
2001 – 2007 Higher General Secondary Education, Erfgooiers College, Huizen

### Research positions

Dec 2019 – Dec 2023 Post-doctoral researcher, GROW School for Oncology and Reproduction, MUMC+, Maastricht (0.1fte)  
May 2016 – Dec 2019 PhD-Candidate (Dutch Cancer Society, project 2018-8023)  
*Dissertation: "Towards de-escalation of axillary management after neoadjuvant chemotherapy in breast cancer"*  
*Promotor: prof. dr. M.L. Smidt, MUMC+, Maastricht*  
*Co-promotoren: dr. L.B. Koppert, dr. E.J.T. Luiten*  
*Date of thesis defense: 18<sup>th</sup> of December, 2019*  
Aug 2018 – Dec 2018 Research-assistant, Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, USA (supervisor dr. Hunt)  
2009 Research summer exchange project on the association between HPV and retinoblastoma, Centro de Onco-Hematologia Pediátrica, Recife, Brazil

### Most recent scientific publications

(for full list see <https://www.ncbi.nlm.nih.gov/myncbi/1Lmuld9IEa1A5/bibliography/public/>)

Wintraecken VM, Boersma LJ, van Roozendaal LM, de Vries J, van Kuijk SMJ, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, van de Vijver KKBT, Westenberg AH, de Wilt JHW, Smidt ML, **Simons JM**; BOOG 2013-08 group  
"Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial". *Radiother Oncol.* 2024 Feb;191:110069. doi: 10.1016/j.radonc.2023.110069.

de Wild SR, Koppert LB, de Munck L, Vrancken Peeters MTFD, Siesling S, Smidt ML, **Simons JM**.  
"Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study". *Breast Cancer Res Treat.* 2023 Dec 22. doi: 10.1007/s10549-023-07178-6.

Verreck EEF, van Steenhoven JEC, Kuijer A, van Maaren MC, **Simons JM**, Siesling S, van Dalen T  
“Trends of Axillary Treatment in Sentinel Node-Positive Breast Cancer Patients Undergoing  
Mastectomy”. *Ann Surg Oncol*. 2023 Sep;30(9):5623-5632. doi: 10.1245/s10434-023-13568-3.

**Simons JM\***, van Nijnatten TJA\*, van der Pol CC, van Diest PJ, Jager A, van Klaveren D, Kam BLR,  
Lobbes MBI, de Boer M, Verhoef C, Sars PRA, Heijmans HJ, van Haaren ERM, Vles WJ, Contant CME,  
Menke-Pluijmers MBE, Smit LHM, Kelder W, Boskamp M, Koppert LB, Luiten EJT, Smidt ML.  
“Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node  
Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.” *JAMA Surg*. 2022 Nov  
1;157(11):991-999. doi: 10.1001/jamasurg.2022.3907. \*Co-first author.

De Wild SR, de Munck L, **Simons JM**, Verloop J, van Dalen T, Elkhuzen PHM, Houben RMA, van  
Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PM, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ  
“De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM;  
BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study”. *Lancet Oncology*.  
2022 aug S1470-2045(22)00482-X. doi: 10.1016/S1470-2045(22)00482-X

De Wild SR, **Simons JM\***, Vrancken Peeters MTFD, Smidt ML, Koppert LB; MINIMAX Group  
“MINImal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy  
in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX)”. *Clin  
Breast Cancer*. 2022 Jan;22(1):e59-e64. doi: 10.1016/j.clbc.2021.07.011. Epub 2021 Jul 26. \*Co-first  
author.

De Wild SR, **Simons JM**, Vrancken Peeters MTFD, Smidt ML, Koppert LB  
“De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic  
Therapy”. *Breast Care (Basel)*. 2021 Dec;16(6):584-589. doi: 10.1159/000518376

Samiei S, **Simons JM**, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML; EUBREAST Group  
“Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer  
Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-  
analysis”. *Jama Surg*. 2021 Jun. 1;156(6):e210891. doi: 10.1001/jamasurg.2021.0891

**Simons JM**, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian  
I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS  
“Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After  
Neoadjuvant Chemotherapy for Breast Cancer Patients”. *Ann Surg Oncol*. 2020 Jan 8. doi:  
10.1245/s10434-020-09542-y.

Filipe MD, **Simons JM**, Moeliker L, Waaijer L, Vriens MR, van Diest PJ, Witkamp AJ.  
“Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge”. *Breast  
Cancer*. 2020 Nov 12. doi: 10.1007/s12282-020-01184-y.

**Simons JM**, Jacobs JG, Roijers JP, Beek MA, Boonman-de Winter LJM, Rijken AM, Gobardhan PD,  
Wijsman JH, Tetteroo E, Heijns JB, Yick CY, Luiten EJT.  
“Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-  
conserving surgery compared to mastectomy in a large single-centre cohort study”. *Breast Cancer Res  
Treat*. 2020 Oct 19. doi: 10.1007/s10549-020-05966-y.